Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Paul Angulo

Showing results (101-110 of 115) with videos related to

Pageof 12
Sort By:
Digestive Diseases and Sciences|March 4, 2009
Moexipril for treatment of primary biliary cirrhosis in patients with an incomplete response to ursodeoxycholic acidPhunchai Charatcharoenwitthaya, Jayant A Talwalkar, Paul Angulo, et al.
Anticancer Research|July 4, 2012
The role of PI3K/mTOR inhibition in combination with sorafenib in hepatocellular carcinoma treatmentRoberto Gedaly, Paul Angulo, Changguo Chen, et al.
Digestive Diseases and Sciences|December 26, 2014
The evaluation of hepatic fibrosis scores in children with nonalcoholic fatty liver diseaseSana Mansoor, Lisa Yerian, Rohit Kohli, et al.
Hepatology (Baltimore, Md.)|March 5, 2004
Ursodeoxycholic acid for treatment of nonalcoholic steatohepatitis: results of a randomized trialKeith D Lindor, Kris V Kowdley, E Jenny Heathcote, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|December 18, 2013
Serum ferritin levels lack diagnostic accuracy for liver fibrosis in patients with nonalcoholic fatty liver diseasePaul Angulo, Jacob George, Christopher P Day, et al.
Journal of Cachexia, Sarcopenia and Muscle|August 6, 2016
Sarcopenic obesity and myosteatosis are associated with higher mortality in patients with cirrhosisAldo J Montano-Loza, Paul Angulo, Judith Meza-Junco, et al.
The Journal of Surgical Research|June 18, 2013
PKI-587 and sorafenib alone and in combination on inhibition of liver cancer stem cell proliferationRoberto Gedaly, Roberto Galuppo, Yolanda Musgrave, et al.
Hepatology (Baltimore, Md.)|October 14, 2009
Betaine for nonalcoholic fatty liver disease: results of a randomized placebo-controlled trialManal F Abdelmalek, Schuyler O Sanderson, Paul Angulo, et al.
Hepatology (Baltimore, Md.)|June 21, 2011
The natural history of nonalcoholic fatty liver disease with advanced fibrosis or cirrhosis: an international collaborative studyNeeraj Bhala, Paul Angulo, David van der Poorten, et al.
Gastroenterology|May 4, 2015
Liver Fibrosis, but No Other Histologic Features, Is Associated With Long-term Outcomes of Patients With Nonalcoholic Fatty Liver DiseasePaul Angulo, David E Kleiner, Sanne Dam-Larsen, et al.
Pageof 12

Showing results (101-110 of 115) with videos related to

Sort By:
Pageof 12
Digestive Diseases and Sciences|March 4, 2009
Moexipril for treatment of primary biliary cirrhosis in patients with an incomplete response to ursodeoxycholic acidPhunchai Charatcharoenwitthaya, Jayant A Talwalkar, Paul Angulo, et al.
Anticancer Research|July 4, 2012
The role of PI3K/mTOR inhibition in combination with sorafenib in hepatocellular carcinoma treatmentRoberto Gedaly, Paul Angulo, Changguo Chen, et al.
Digestive Diseases and Sciences|December 26, 2014
The evaluation of hepatic fibrosis scores in children with nonalcoholic fatty liver diseaseSana Mansoor, Lisa Yerian, Rohit Kohli, et al.
Hepatology (Baltimore, Md.)|March 5, 2004
Ursodeoxycholic acid for treatment of nonalcoholic steatohepatitis: results of a randomized trialKeith D Lindor, Kris V Kowdley, E Jenny Heathcote, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|December 18, 2013
Serum ferritin levels lack diagnostic accuracy for liver fibrosis in patients with nonalcoholic fatty liver diseasePaul Angulo, Jacob George, Christopher P Day, et al.
Journal of Cachexia, Sarcopenia and Muscle|August 6, 2016
Sarcopenic obesity and myosteatosis are associated with higher mortality in patients with cirrhosisAldo J Montano-Loza, Paul Angulo, Judith Meza-Junco, et al.
The Journal of Surgical Research|June 18, 2013
PKI-587 and sorafenib alone and in combination on inhibition of liver cancer stem cell proliferationRoberto Gedaly, Roberto Galuppo, Yolanda Musgrave, et al.
Hepatology (Baltimore, Md.)|October 14, 2009
Betaine for nonalcoholic fatty liver disease: results of a randomized placebo-controlled trialManal F Abdelmalek, Schuyler O Sanderson, Paul Angulo, et al.
Hepatology (Baltimore, Md.)|June 21, 2011
The natural history of nonalcoholic fatty liver disease with advanced fibrosis or cirrhosis: an international collaborative studyNeeraj Bhala, Paul Angulo, David van der Poorten, et al.
Gastroenterology|May 4, 2015
Liver Fibrosis, but No Other Histologic Features, Is Associated With Long-term Outcomes of Patients With Nonalcoholic Fatty Liver DiseasePaul Angulo, David E Kleiner, Sanne Dam-Larsen, et al.
Pageof 12